Abstract
The present disclosure provides a method comprised of one or a combination of ir-lncRNA signatures to predict the clinical outcome of cancer patients, improve prognostic stratification of patients and guide cancer treatment decisions.
Original language | English |
---|---|
Patent number | US2023348994 |
IPC | C12Q 1/ 6886 A I |
Priority date | 28/04/23 |
Publication status | Published - 2 Nov 2023 |